Management of Elevated INR in Patients with History of Stroke on Warfarin

Assessment and Management

• For a patient with an INR of 3.48 on warfarin therapy with a history of stroke, the next dose of warfarin should be omitted and subsequent doses should be reduced by approximately 10-15% of the weekly total dose, as recommended by the American College of Cardiology 1, 2
• The patient's INR of 3.48 is above the therapeutic range (typically 2.0-3.0) but below 5.0, which is considered a mild elevation without immediate risk of serious bleeding, according to the American College of Cardiology 1, 2
• Patients with a history of stroke are at higher risk for thromboembolic events if anticoagulation is excessively reduced, as stated by the American College of Chest Physicians and the American Heart Association 3, 4
• No vitamin K administration is needed at this INR level, as recommended by the American College of Cardiology 1, 5
• The risk of bleeding increases exponentially with INR values above 3.0, but becomes clinically significant primarily when INR exceeds 5.0, according to the American College of Cardiology 1
• Patients with history of stroke should maintain an INR target of 2.0-3.0 to minimize the risk of recurrent thromboembolic events, as recommended by the American Heart Association 4
• Elderly patients (>65 years) have higher bleeding risk at any given INR level and may require more cautious management, according to the American College of Cardiology 8
• Excessive dose reduction (more than 20%) may lead to subtherapeutic INR and increased stroke risk, as warned by the American College of Chest Physicians 3
• Unnecessary vitamin K administration for INR <5.0 without bleeding may lead to warfarin resistance, as cautioned by the American College of Cardiology 1, 6
• Failure to identify the cause of INR elevation, such as medication changes, dietary changes, or illness, may lead to inadequate management, as emphasized by the American College of Cardiology and the American Geriatrics Society 1, 7
• Inadequate follow-up, including timely INR rechecks, may result in delayed recognition of subtherapeutic or supratherapeutic anticoagulation, as highlighted by the American Geriatrics Society 7